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Relationship of serum prolactin with severity
of drug use and treatment outcome in cocaine
dependence
Rationale
Alteration in serum prolactin (PRL) levels may reflect changes in central dopamine activity,
which modulates the behavioral effects of cocaine. Therefore, serum PRL may have a potential
role as a biological marker of drug severity and treatment outcome in cocaine dependence.

Objective
We investigated whether serum PRL levels differed between cocaine-dependent (CD) subjects
and controls, and whether PRL levels were associated with severity of drug use and treatment
outcome in CD subjects.

Methods
Basal PRL concentrations were assayed in 141 African–American (AA) CD patients attending an
outpatient treatment program and 60 AA controls. Severity of drug use was assessed using the
Addiction Severity Index (ASI). Measures of abstinence and retention during 12 weeks of
treatment and at 6-month follow-up were employed as outcome variables.

Results
The basal PRL (ng/ml) in CD patients (9.28±4.13) was significantly higher than controls
(7.33±2.94) (t=3.77, P<0.01). At baseline, PRL was positively correlated with ASI-drug (r=0.38,
P<0.01), ASI-alcohol (r=0.19, P<0.05), and ASI-psychological (r=0.25, P<0.01) composite
scores, and with the quantity of cocaine use (r=0.18, P<0.05). However, PRL levels were not
significantly associated with number of negative urine screens, days in treatment, number of
sessions attended, dropout rate or changes in ASI scores during treatment and at follow-up. Also,
basal PRL did not significantly contribute toward the variance in predicting any of the outcome
measures.

Conclusion
Although cocaine use seems to influence PRL levels, it does not appear that PRL is a predictor of
treatment outcome in cocaine dependence.
A wealth of evidence shows that cocaine binds to the dopamine transporter and blocks the neuronal
reuptake of dopamine, resulting in increased synaptic dopamine concentrations (Kuhar et al. 1991; Carroll

et al. 1992). These dopaminergic effects appear to be critical in mediating the rewarding effects of
cocaine (Dackis and Gold 1985; Koob et al. 1994). In contrast, repeated cocaine exposure is reported to
decrease levels of extracellular dopamine in the brain (Weiss et al. 1992). While investigators have
postulated that this depletion in dopamine after chronic cocaine use may be associated with craving
(Dackis and Gold 1985; Gawin and Kleber 1985), other data have not been consistent with this
hypothesis. For example, clinical trials have generally failed to establish the effectiveness of dopamine
agonists in promoting cocaine abstinence (Kosten et al. 1992). It seems that in addition to dopamine,
other neurotransmitter and second messenger systems are also affected by cocaine and that the addictive
properties of cocaine may be related to the complex interactions between these multiple neuronal systems
(Nestler and Aghajanian 1997; Nestler 2001).
Due to its interactions with dopamine and other neuromodulatory systems, cocaine has important effects
on anterior pituitary, gonadal, and adrenal hormones, particularly prolactin (PRL) (Mello and Mendelson
1997). The secretion of PRL is mediated, in part, by the inhibitory influence of the tuberoinfundibular
dopaminergic neurons (Neill et al. 1981) and therefore changes in basal PRL have been considered to
reflect changes in central dopamine activity (Tuomisto and Mannisto 1985). However, the specificity of
basal PRL as a biological measure of dopamine remains a matter of debate, since it is reported to be
affected by a wide range of factors such as diet (Chakravarty et al. 1982), smoking (Martin et al. 1987),
and stress (Martin et al. 1987). PRL secretion may also be influenced by serotonergic neurotransmission
(Fishbein et al. 1989), and it remains unclear to what extent it is an accurate measure of dopamine in the
reward pathways. Nevertheless measurement of peripheral PRL levels in the basal state or as a response
to a challenge to dopamine agonists has been widely employed as an estimate of central dopamine activity
in psychopharmacological studies (Joyce et al. 1995; Appleberg et al. 2000; Basturk et al. 2001).

Animal experiments have shown decreased PRL levels following acute administration and elevation in
PRL after chronic administration of cocaine (Baumann and Rothman 1993; Levy et al. 1994). Among
humans, however, the findings have not been consistent. PRL levels have been found to be increased
(Mendelson et al. 1988; Teoh et al. 1990; Kranzler and Wallington 1992), decreased (Gawin and Kleber
1985), or unchanged (Swartz et al. 1990; McDougle et al. 1992; Baumann et al. 1995) among cocaine
abusers. The conflicting results may be due to differences in assay techniques, timing or extent of recent
cocaine use, or sample characteristics.
Research examining the relationship between biological markers such as PRL and treatment outcome
among cocaine abusers has been sparse. Weiss et al. (1994) found that cocaine patients with
hyperprolactinemia during inpatient treatment were less likely to remain abstinent at 6 months compared
with patients with normal PRL levels. Similarly, in a study of hospitalized cocaine abusers, Kranzler and
Wallington (1992) reported that patients with hyperprolactinemia were more likely to drop out of
treatment and receive premature discharges. These findings were also replicated in an outpatient study,
which found that hyperprolactinemia may be associated with an increased risk of relapse to cocaine abuse
(Baumann et al. 1995). Supporting these findings, in a study on a smaller sample of cocaine abusers, we
found that higher PRL levels were related to poor treatment response (Patkar et al. 2002). Taken together,
this evidence suggests that elevated PRL may indicate adverse prognosis for cocaine patients. However
negative results have also been reported. For example, in controlled and uncontrolled clinical trials with
bromocriptine, plasma PRL was not correlated with intensity of withdrawal, symptom improvement or
drop-out rate in cocaine patients (Eiler et al. 1995; Teller and Deveny 1988). Along the same lines, Satel
et al. (1991) found that PRL levels after cessation of cocaine use are not a good predictor of withdrawal
severity and need for treatment in hospitalized cocaine patients.

This study had two objectives. First to determine whether basal PRL levels in cocaine-dependent (CD)
patients differed from those in controls, and second, to examine the relationship of basal PRL levels with
measures of drug severity and with treatment outcome in CD patients. The present study differed from
our previous study (Patkar et al. 2002) in three respects. The sample was nearly twice as large, the drug
severity and outcome measures were more comprehensive and follow-up data was included.

Materials and methods

Subjects
One hundred and forty-one subjects with a DSM-IV (American Psychiatric Association 1994)
diagnosis of cocaine dependence were recruited from a publicly funded, university-affiliated,
intensive outpatient cocaine treatment program in Philadelphia. The sample was restricted to
African–American (AA) subjects only because over 90% of the patient population in the
program were of AA background. The study was approved by the Institutional Review Board of
the University. Following a description of the study, written informed consent was obtained from
individuals who volunteered for the study. The structured clinical interview (SCID) for DSM-IV
Axis I Disorders (First et al. 1997) was then administered to study participants. Individuals with
a diagnosis of schizophrenia, major depression, bipolar disorder, schizoaffective disorder, an
unstable medical illness, those who were pregnant or received psychotropic medications in the
previous 12 weeks were excluded. If patients used more than one substance, they were included
only if their primary drug of abuse was cocaine. The subjects were recruited between October
1997 and February 2002.

Sixty AA controls were recruited from those responding to local advertisements. Consenting and
screening procedures were similar to those followed for cocaine subjects. Control subjects were
excluded if they had a history of substance abuse (tobacco use was not an exclusion criterion), a
major psychiatric disorder (schizophrenia, major depression or bipolar disorder), a positive urine
drug screen or were taking psychotropic medications in the previous 12 weeks.

Assessments
Eligible subjects and controls were assessed using the Beck depression inventory (BDI) (Beck
and Steer 1987). The BDI is a widely used, self-report questionnaire that requires about 10 min
to complete. Smoking status was rated on the Fagerstrom test for nicotine dependence (FTND), a
widely used and validated six-item questionnaire to assess severity of smoking (Fagerstrom and
Schneider 1989; Heatherton et al. 1991). Severity of drug use in cocaine subjects was assessed
using the Addiction Severity Index (ASI) (McLellan et al. 1985, 1992). The ASI is a 30–40 min
structured interview assessing seven problem areas in substance dependent persons. For each
domain, a composite score that ranges from 0 (minimum) to 1 (maximum) is provided to assess
the adequacy of functioning in these areas during the previous 30 days. All the assessments were
performed at admission to the treatment program at least 2 weeks prior to the blood draw for
PRL determination.

PRL determination
To minimize any effects of recent cocaine use on PRL, subjects had blood samples withdrawn
after at least 2 weeks of abstinence from cocaine. The 2-week abstinence period was documented
by monitoring urines twice a week. On the test day, subjects were asked to come in the morning
after an overnight fast and instructed not to smoke. Aliquots of 20 ml venous blood were
collected in EDTA-treated tubes, and the sera were separated and frozen at −20°C. Samples were
identified by code numbers for blinding purposes. PRL was assayed using the Active PRL DSL4500 Immunoradiometric Assay Kit (Diagnostic Systems Laboratories, Tex., USA). This assay
employs a standardized two-site immunoradiometric assay technique (Miles et al. 1974) to
provide quantitative estimates of PRL in the serum. The assay sensitivity was 0.1 ng/ml and
specificity tests carried out by the manufacturer indicate that other hormones were unlikely to
cross-react with the PRL-antibody. The interassay and intraassay coefficients of variation were
11.2 and 4.0%, respectively.

Treatment approach
The study participants received the same treatment that was offered to the non-research patients
in the program. Treatment consisted of outpatient group counseling sessions 3 times a week,
each session lasting for 3 h for a total of 12 weeks. In addition, patients participated in one 45min individual counseling session per week over the 12-week period. Patients completing the
intensive program were offered other treatment options, including an aftercare program which
included one individual counseling session per week for up to 6 months. The treatment approach
was problem oriented and focused on attaining well-defined goals. Pharmacotherapy was not
routinely used, but was available when needed and attendance at self-help meetings was
encouraged. Such a multimodal approach seems to be fairly typical of many outpatient addiction
treatment programs. The research data were not made available to the treatment providers while
the study was active.

Follow-up
Follow-up interviews for CD subjects were performed at 6 months after the end of 12-week
treatment by research assistants and included administration of an abbreviated form of the ASI
and urine drug screens. The follow-up personnel were blind to the treatment condition or PRL
measurements. Ninety (64%) of the subjects were followed up.

Outcome measures
In-treatment, end-of-treatment and follow-up assessments were performed to provide objective
estimates of abstinence, retention and attrition from treatment. These were as follows: (a)
Number of negative urines: urine drug screens (UDS) were obtained for all subjects at admission
to the treatment program and following each group counseling session. The UDS was a one-step
immunoassay for the detection of cocaine, opiates, cannabinoids, barbiturates, and
amphetamines. A urine sample was considered positive if it was positive for any substance. The
number of UDS negative for all tested substances was used as a measure of substance use during
treatment. (b) Days in treatment: this reflects treatment retention and was recorded as the number

of days between the first and last counseling session. (c) Number of group and individual
counseling sessions attended: the total number of group and individual sessions attended by each
patient offers another estimate of treatment retention and participation. (d) Dropouts: these were
defined as individuals who attended no more than two treatment sessions during the 12-week
program. (e) Symptom reduction during treatment and at follow-up: the baseline (admission)
composite score in each of the seven problem areas of the ASI minus the last composite score
obtained during the 12-week counseling period was employed as a measure of problem reduction
during treatment. Similarly, the follow-up composite scores on the ASI were subtracted from the
baseline ASI to compute problem reduction at follow-up.

Statistical analyses
PRL levels and demographic characteristics were compared between cases and controls using
two-tailed t-tests for continuous variables and chi-square tests for categorical variables. Pearson
product moment correlation was employed to correlate PRL levels with measures of drug
severity. Pearson or biserial correlations, as appropriate were used to examine the relationship of
PRL with continuous and dichotomous outcome variables. Tests of partial correlation were used
to control for effects of potential confounders on the relationship between primary and dependent
variables. Subsequently, the distribution of basal PRL scores among cocaine patients was
examined and a split was performed at PRL values that were 1 standard deviation (SD) above the
mean values to capture a more severe subgroup. This “higher PRL” subgroup was compared
with rest of the patients using two-tailed t-tests and chi-square analyses to examine for
differences in severity and outcome variables. Hierarchical regression models were used to
predict outcome measures from combinations of independent variables, and to examine whether
basal PRL contributed towards predicting outcome.

Results

Subjects
Out of 262 AA CD patients screened, a total of 141 subjects were enrolled in the study. Excluded subjects
were: 31 patients with current major psychiatric disorder or receiving psychotropic medications, 78
patients who did not meet the criteria for 2-week abstinence from cocaine before PRL determination,
three patients with serious medical disorders, three patients who withdrew consent, and six subjects
whose blood samples could not be analyzed for technical reasons. Sixty AA controls were recruited after
screening 119 volunteers and excluding 35 persons who either had a positive urine drug screen or were
unable to provide a urine sample, 19 individuals who had a diagnosis of major psychiatric disorder or
were taking psychotropic medications, two patients with unstable medical illnesses, and three persons
whose blood samples could not be analyzed. Table 1 summarizes the demographic and clinical
characteristics of the sample. The CD patients and controls did not differ significantly in gender.
However, significantly more patients were older, single and unemployed compared to controls. The
admission UDS for 35% of the patients was positive for cocaine. Patients whose UDS were cocainenegative at admission reported on average 14.4 days of abstinence from cocaine prior to admission. A
significant proportion of the CD subjects had additional substance abuse and dependence diagnoses.
About 53% had abused or were dependent on alcohol, approximately 82% were nicotine dependent,
nearly 31% were abusing or dependent on marijuana, and about 14% had opioid abuse or dependence

during their lifetime or at the present time. About 35% of controls smoked and none abused alcohol
during the study period. The mean FTND scores were significantly higher among cocaine subjects
(4.92±2.28) compared with controls (2.32±2.70) (t=6.77, df=198, P<0.01), indicating that cocaine
patients were more severely nicotine dependent compared to controls. Cocaine patients smoked 15.8±4.6
cigarettes per day compared to controls (7.4±3.6 cigarettes per day) (t=8.16, df=198, P<0.001). Because
tobacco smoking has been found to influence PRL levels, we examined whether it could have confounded
the results. PRL levels were not significantly correlated with FTND scores in cocaine patients (r=0.09) or
controls (r=0.12). Similarly, no significant correlation was observed between FTND scores or any of the
outcome measures—number of negative urine screens (r=−0.12), days in treatment (r=0.03), number of
treatment sessions (r=−0.09) and dropout (χ2=1.68). No significant correlation was found between PRL
levels and number of cigarettes smoked per day among cocaine patients (r=0.07) or controls (r=0.10).
Also, cigarettes per day were not correlated with any of the outcome measures (all r<0.12, P>0.05).
Because there were between-subject variations in time from admission to blood draw for PRL
determination, we examined and found no association between this factor and PRL levels (r=−0.09).
Body mass index (BMI) has been found to be positively associated with PRL levels in some studies
(Komorowski et al. 2000). We found no significant difference in BMI between cocaine patients and
controls (Table 1) and no significant association between BMI and PRL in patients or controls (r ranged
from 0.07 to 0.09).

Table 1
Characteristics of cocaine-dependent patients and controls
Characteristics
Age (years)
Male
Single
Unemployed
Education
Beck depression
Body mass index (kg/m2)
Time from admission to blood
draw (days)
Cocaine usea
Age at first use
Quantity (g/day)
Frequency (days/week)
Duration (years)
Addiction severity (ASI)b
Drug

Cocaine patients (n=141)
mean (SD)
36.29 (6.35)
72%
73%
85%
11.60 (1.77)
11.84 (7.79)
25.1 (6.2)
17.7 (8.2)
20.42 (4.13)
1.23 (0.54)
5.5 (1.6)
14.62 (7.78)
0.24 (0.23)

Controls (n=60)
mean (SD)
32.60 (5.74)
61%
46%
29%
14.31 (3.13)
6.24 (3.43)
26.4 (4.9)

t/χ2
t=3.89***
χ2=2.31
χ2=6.23**
χ2=40.61***
t=3.62***
t=5.26***
t=1.89

Characteristics
Alcohol
Employment
Family
Legal
Medical
Psychological

Cocaine patients (n=141)
mean (SD)
0.23 (0.26)
0.85 (0.27)
0.13 (0.21)
0.04 (0.15)
0.07 (0.16)
0.17 (0.21)

Controls (n=60)
mean (SD)

t/χ2

*P<0.05, **P<0.01, ***P<0.001, all t-tests two-tailed, df=193–199 for t-tests, df=1 for χ2
a

Measures of drug use only obtained for cocaine-dependent patients

b

Measures of drug use only obtained for cocaine-dependent patients. Represent composite scores
on the ASI

PRL levels among cocaine-dependent patients and controls
The assay range for normals was 2.9–17.1 ng/ml for men and 3.2–25.3 ng/ml for women.
Figure 1 summarizes the overlap of cocaine patients and controls across the range of basal PRL.
Figure 2 summarizes the distribution of individual PRL values among patients and controls. The
basal PRL levels (ng/ml) in CD patients (9.28±4.13) were significantly higher than controls
(7.33±2.94) (t=3.77, df=199, P<0.01). There were no significant differences in PRL levels
between men (9.01±4.03) and women (9.92±4.35) in CD patients (t=1.19, df=139, P=0.24) or
controls (men=7.20±2.67; women=7.55±3.37, t=0.45, df=58, P=0.65). Hyperprolactinemia was
detected in five CD men (PRL >17.1 ng/ml) but not in any CD women (PRL >25.3 ng/ml). None
of the controls had hyperprolactinemia. The difference in basal PRL between cocaine patients
and controls continued to remain significant after excluding the five patients with
hyperprolactinemia (t=3.11, df=194, P<0.01). Since cocaine patients were significantly older
than controls, we examined and found no correlation between age and PRL (P=0.11).
Fig. 1
Bar graph showing distribution of cocaine-dependent patients and controls across the range of
basal prolactin levels controls (normal assay range: 2.9–17.1 ng/ml for men and 3.2–25.3 ng/ml
for women)
Fig. 2
Scatterplot showing distribution of basal prolactin values among cocaine-dependent subjects and
controls

PRL levels and severity of addiction in cocaine-dependent patients
We explored the relationship between measures of cocaine use and PRL levels. As summarized
in Table 2, PRL showed a significant positive correlation with quantity of cocaine use and
composite scores on the drug, alcohol and psychological scales of the ASI. The correlation of
PRL with amount of cocaine use is summarized in Fig. 3. A trend towards a negative correlation
of PRL with length of abstinence was also observed (r=−0.17, P=0.07, two tailed). Correlations
of PRL with other measures of ASI and cocaine use were not significant (Table 2). The
correlations of PRL with the severity measures continued to remain significant after controlling
for BDI scores (partial correlation coefficient r ranged from 0.19 to 0.40, P ranged from <0.05 to
<0.001). We also reanalyzed the data by comparing the higher PRL group (PRL >13.42) (mean
PRL >1 SD above the mean) (n=26) with the rest of the patients (mean PRL ≤13.42) (n=115)
across the severity measures. The strength and direction of the between-group differences in
severity measures were consistent with the correlations shown in Table 2 (t ranged from 0.09 to
2.86, df=130–139, P ranged from <0.01 to <0.05).
Table 2
Correlation between PRL levels and measures of cocaine use (n=138)
Cocaine use
Correlation coefficient r
Quantity (g/day)
0.18*
Frequency (days/week)
0.09
Duration (years)
0.11
Length of abstinence (days) −0.17
Addiction severity (ASI)a
Drug
0.38**
Alcohol
0.19*
Employment
0.11
Family
0.15
Legal
0.09
Medical
0.07
Psychological
0.25**
b
Positive admission urine
0.15
*P<0.05; **P<0.01
a

Composite scores on the ASI

b

Biserial correlation for dichotomous variable

Fig. 3
Correlations between basal prolactin levels and amount of cocaine use

PRL levels and outcome measures during treatment and at follow-up
We found that cocaine patients had remained in treatment for 62.8±47.1 days, and attended
15.1±9.7 group and 4.4±7.4 treatment sessions. They provided 5.4±4.8 urine samples that were
negative for all drugs and 7.6±3.9 urine samples that were negative only for cocaine. The
proportion of 2-week dropouts was 30%. We first examined whether change in symptoms
occurred in the sample during treatment and at follow-up by comparing the mean pretreatment
and end of treatment ASI composite scores and the mean pretreatment and follow-up ASI scores.
At the end of the treatment program, statistically significant reduction in ASI composite scores
had occurred in five of the seven areas functioning during treatment: drug (t=3.08,P<0.01),
alcohol (t=2.92, P<0.01), medical (t=2.68, P<0.05), family (t=2.73, P<0.05) and psychiatric
(t=3.61, P<0.01). No differences were observed in ASI composite scores for employment
(t=0.06) and legal (t=0.11) domains. At 6-month follow-up, the symptom reduction on ASI was
maintained in four domains: drug (t=2.81, P<0.01), alcohol (t=2.82, P<0.01), medical (t=2.44,
P<0.05), and psychiatric (t=2.97, P<0.01).
We then determined whether basal PRL was associated with any of the outcome measures
among cocaine patients. PRL was not significantly correlated with number of urines negative for
all drugs (r=−0.08), number of cocaine-negative urines (r=−0.10), days in treatment (r=0.02),
number of group (r=0.11) or individual (r=0.10) sessions or dropout rate (χ2=2.31). Because PRL
was related to severity measures, we re-examined the relationship between PRL and outcome
measures adjusting for baseline ASI scores. The correlations of PRL with outcome measures
continued to be non-significant (all partial correlation coefficients r<0.11). We then compared
the higher PRL group (PRL >13.42) (n=26) with the rest of the patients (mean PRL ≤13.42)
(n=115) across the outcome measures during treatment and at follow-up. The two groups did not
differ across measures treatment retention, abstinence, treatment participation and symptom
reduction during treatment or at follow-up (t-values ranged from 0.28 to 1.12, χ2 ranged from
0.61 to 1.22, P>0.05 in each case).
Since patients who were mandated to attend our program by the courts were likely to stay longer
in treatment, we evaluated and found no significant differences in their PRL levels (9.32±4.18)
compared to patients who were voluntary referrals (9.22±4.11) (t=0.41, df=139, P=0.73).

Basal PRL as a predictor of outcome among cocaine patients
Hierarchical regressions were used to determine whether basal PRL was associated with outcome
measures after covarying for demographics (age and educational level), severity of drug use (ASI-drug
and alcohol scores) and behavioral measures (Beck depression measures). These variables have been
associated with poor treatment outcome for cocaine patients. Step 1 entered educational level, step 2
added ASI-drug and alcohol composite scores and step 3 examined whether basal prolactin levels added
any significant variance. The results are summarized in Table 3.
Table 3

Regression analysis for predictors of outcome among cocaine patients

Outcome variables
Days in treatmenta
Step 1. Age and education level

β

R2

F/χ2

0.27 0.08**

Step 2. ASI-drug, ASI-alcohol and BDI −0.18 0.12
Step 3. Basal prolactin
Negative urines during treatmentb

−0.01 0.12

Step 1. Age and education level

0.22 0.05*

2.28

Step 2. ASI-drug, ASI-alcohol and BDI −0.13 0.09
Step 3. Basal prolactin
Treatment sessions attendedc

−0.07 0.09

Step 1. Age and education level

0.23 0.08*

1.71

Step 2. ASI-drug, ASI-alcohol and BDI −0.12 0.12
Step 3. Basal prolactin
Follow-up ASI drug scoresd

−0.01 0.12

Step 1. Age and education level

−0.15 0.01*

1.77

Step 2. ASI-drug, ASI-alcohol and BDI 0.45 0.22**
Step 3. Basal prolactin
Follow-up urine drug screene

−0.01 0.22** 3.13

Step 1. Age and education level

−0.09 0.01

Step 2. ASI-drug, ASI-alcohol and BDI −0.13 0.26*
Step 3. Basal prolactin
*P<0.05, **P<0.01
a

F(6,107)=2.28, P<0.05

b

c

F(6,107)=1.71, P=0.12

F(6,107)=1.77, P=0.15

d

F(6,107)=3.13, P<0.01

χ =39.68, P=0.39

e 2

−0.10 0.28* 0.285

The results indicated that although the variables entered in the model predicted certain outcome
measures (days in treatment and follow-up measures of drug severity), basal PRL did not
contribute to any significant increase in variance in predicting any of the outcome measures. Five
male cocaine patients were noted to have absolute hyperprolactinemia (PRL >17.1). These
patients did not fare differently than the rest of the male cocaine patients on outcome measures.
None of the controls had hyperprolactinemia.
Because the results were negative, i.e. PRL did not predict any of the outcome measures, we
conducted a post hoc power analysis to determine the magnitude of relationship between PRL
and outcome that could be detected in the present study. For this purpose, we selected positive or
negative urine drug screens as an outcome measure of abstinence. The analysis estimated that a
sample of 141 subjects could detect a 11% relationship between PRL and urine drug screens at
end of treatment (α=0.05, power=80). A weak and statistically non-significant relationship of 2%
was observed between PRL and urine drug screens in the study. For this relationship to reach a
0.05 level of significance, a sample size of nearly 600 cocaine patients is required, indicating that
for all practical purposes, PRL did not have a meaningful association with treatment outcome.

Discussion
Our study has three main findings of interest. First, the results suggest that basal PRL levels are
significantly higher in CD patients compared to controls. Second, we found a positive
association between measures of drug severity and PRL. Finally, PRL was not associated with
outcome measures during treatment or at follow-up.
The higher basal PRL levels found among cocaine patients relative to controls in our study
replicate our previous findings (Patkar et al. 2002) and are consistent with several reports of
increased PRL levels among chronic cocaine abusers (Cocores et al. 1986; Mendelson et al.
1988; Teoh et al. 1990; Kranzler and Wallington 1992; Miller et al. 1993). Because secretion of
PRL is mediated by the inhibitory influence of the tuberoinfundibular dopaminergic neurons
(Neill et al. 1981), the increased PRL levels may reflect decreased central dopamine activity in
CD individuals. However, PRL is an indirect measure of dopamine in the brain and may not
accurately reflect mesolimbic dopaminergic activity.
Our results are in contrast to other investigators who reported no changes in PRL (Swartz et al.
1990; Baumann et al. 1995; Eiler et al. 1995) or found lower PRL levels (Gawin and Kleber
1985) among cocaine abusers. Differences in sample characteristics and assay techniques may
account for the inconsistencies in findings in the literature. For example mean duration of
cocaine use was 14.6 years among our patients as opposed to 3.6 years in Gavin and Kleber’s
sample (1985) and we studied both men and women in contrast to only men in studies conducted
by Swartz et al. (1990) and Eiler et al. (1995).
We also found a modest positive correlation of PRL levels with quantity of cocaine use and the
certain ASI domains. Although other severity measures were not significantly correlated with
PRL, the relationships were in the expected direction. Therefore, it is unlikely that the results
could be chance errors occurring due to multiple testing. The failure to find a significant
relationship between cocaine positive urine drug screen at admission and PRL could be

explained by the timing of PRL determination. We measured PRL levels after at least 2 weeks of
abstinence to minimize alterations in PRL from acute effects of cocaine. Therefore, the
admission urine screens and PRL determinations were performed at different time points and it
was not surprising that the two measures were not related. Nevertheless, the relationship of drug
severity with PRL levels suggests that the elevated PRL may be a consequence of cocaine use.
Considering the modest strength of the correlations, further research that involves serial
measurements of PRL and quantitative estimates of cocaine may help to clarify the relationship
of cocaine use with PRL.
Unlike our previous findings (Patkar et al. 2002), we did not observe a relationship of baseline
PRL with outcome measures. In our earlier study, although cocaine patients with higher PRL
performed poorly on outcome measures of negative urines and counselor ratings of
improvement, the differences were not statistically significant on the other outcome measures.
We had cautioned that the findings should be considered preliminary and needed replication. In
the present study, we expanded our sample pool, included follow-up data and used more
comprehensive outcome measures. Therefore the data from this study are stronger than our
earlier study. In this context, it is worth noting that the studies supporting a relationship of PRL
with outcome in cocaine dependence were either performed in hospitalized patients, with small
sample sizes or were short-term treatment (Kranzler and Wallington 1992; Weiss et al. 1994;
Baumann et al. 1995). The negative findings from the present study indicate that at least in an
outpatient, primarily psychotherapeutic treatment program for cocaine dependence, serum PRL
seems to have a limited role as a biological marker to predict 12-week and 6-month outcome.
Whether serum PRL has the potential to be a marker of treatment outcome in pharmacological
studies of cocaine patients remains to be clarified.
The strengths of our study include a large sample size, recruitment of controls, 6-month followup data and controlling for potential confounders such as depression and tobacco smoking. The
research was conducted with patients from an ongoing, publicly funded treatment program and
therefore the results may be representative of other public sector outpatient programs. However,
interpretations of our findings are subject to certain limitations. First the sample only included
individuals of AA background. Second, we restricted the sample to patients who had a minimum
of 2 weeks abstinence to minimize the acute effects of cocaine. The exclusion of subjects who
had recently used cocaine could have led to a lack of representation of the full range of addiction
severity in the sample. This in turn could have confounded any possible relationship between
PRL and treatment outcome. Third, reflecting the high prevalence of polysubstance abuse in
inner city treatment settings, a substantial proportion of our patients used other substances in
addition to cocaine. Fourth, a single peripheral measurement of PRL can be influenced by
various external factors, and may not fully reflect dopamine activity in the mesolimbic pathways.
Finally, the follow-up rate (64%) was modest, limiting the data captured after 6 months.
In conclusion, although cocaine use seems to influence PRL levels, it does not appear that PRL is
associated with treatment outcome in cocaine dependence. Further studies in this area may
clarify the role of biological markers as predictors of treatment outcome in cocaine dependence.
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